On 27 Feb 2020, GSK launched its First-of-its-kind global partnership to develop transformative tuberculosis treatment regimens
- Published | 01 March 2020
A new global collaboration between philanthropic, non-profit and private sector organizations will work together to speed up the development of new treatment regimens for all TB patients.
A group of philanthropic,
non-profit and private sector organizations has initiated a partnership aimed
at accelerating the development of new "pan-TB" drug schemes for the
treatment of tuberculosis (TB) ready for implementation in phase 3. The systems
will be built to have little to no resistance to drugs and an acceptable safety
profile, and will be better accepted, shorter in length and easier to use than
existing options. These regimens are intended as a central component of efforts
to address emerging TB care issues and challenges.
The leaders of the Project
to Accelerate New Treatments for Tuberculosis (PAN-TB collaboration) – Evotec,
GSK, Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., headquartered in
Japan, the Bill & Melinda Gates Medical Research Institute and the Bill
& Melinda Gates Foundation – committed to using their unique assets,
resources and scientific expertise to accelerate the development of the new
regime.
The PAN-TB partnership plans
to work closely and in a transparent manner with the European Tuberculosis
Regime Accelerator (ERA4 TB), launched in January 2020. New molecular entities
found by ERA4 TB showing promise in initial human studies could later be
integrated into the later-stage, clinical research of the PAN-TB collaboration.
Several companies are part of both ventures, including Evotec, GSK and Johnson
& Johnson, which will help ensure cooperation through partnerships toward
the common goal of advancing drug and regimen production.
TB causes more deaths
worldwide than any other infectious disease, with 10 million new cases reported
in 2018 alone and 1.5 million deaths. Although the number of deaths is
dropping, it is not falling fast enough to meet the global targets of
eliminating tuberculosis at the WHO. There are also serious concerns regarding
the emergence and spread of drug-resistant TB. Drug-resistant TB alone caused
230,000 deaths in 2017-one-third of all AMR-related deaths. TB is also the
leading cause of death for HIV-positive people, responsible for one-third of
deaths of people living with HIV. TB is disproportionately affecting the
world's most vulnerable, with many cases of TB occurring in resource-limited
areas.
Current tools are not
adequate to promote and sustain global progress against TB, "said Trevor
Mundel, Global Health President at the Bill & Melinda Gates Foundation.
"Innovative collaborations are urgently needed, such as PAN-TB
collaboration, to develop new medicines and treatment schemes that can tackle
TB and advance progress towards achieving global TB elimination goals.”
TB causes more deaths
worldwide than any other infectious disease, with 10 million new cases reported
in 2018 alone and 1.5 million deaths. TB is responsible for up to a third of
all antimicrobial-resistance (AMR)-related mortality. The current
drug-sensitive TB regimen, the most common and easiest type of TB to treat,
allows patients to take multiple drugs under clinical follow-up for six months
or more. Patients with drug-resistant TB can not use this regimen and face
treatment regimens that are longer and more complex, often with significant side
effects. Patients currently have to go through additional tests to treat
drug-resistant TB.
The regimens that are being
built by the PAN-TB partnership may help transform TB treatment. A faster and
simpler novel regimen that can treat TB regardless of pre-existing drug
resistance and with a decreased need for drug resistance testing could be of
significant benefit to both patients and health care systems. Via phase 2
clinical efficacy trials, the PAN-TB partnership will identify and evaluate the
potential of pan-TB investigational regimens. Collaborative pre-clinical
research has begun.
Related Blog
- Prebiotics consumption expands in food and beverage applications...
- Online education industry – How has COVID-19 impacted the growth dynamics
- Lithium ion batteries continue to gain phenomenal traction in the automotive sector...
- Personal Protective Equipment Industry – 6 Major Application Sectors Driving...